Literature DB >> 18647662

Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results.

Philippe Major1, Erica Greenberg, Alisa Khan, Elizabeth A Thiele.   

Abstract

Behavioral side effects related to the use of levetiracetam (LEV) in epilepsy are increasingly being recognized. Patients followed in our center have reported improvement of these side effects after starting pyridoxine (vitamin B(6)) supplements. Using mailed questionnaires, retrospective chart reviews, and phone call follow-ups, we analyzed 42 pediatric patients who had been treated with LEV and pyridoxine. Twenty-two patients started pyridoxine after being on LEV, and significant behavioral improvement was observed in nine (41%), no effect in eight (36%), deterioration in four (18%), and an uncertain effect in one. The effects of pyridoxine supplementation were observed during the first week. The remaining patients (20) were already on pyridoxine before LEV was started, started pyridoxine and LEV at the same time, or took pyridoxine intermittently. Pyridoxine is an easily available, inexpensive, and safe therapeutic option. Given these preliminary results, we plan to conduct a placebo-controlled cross-over study to better characterize these observations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647662     DOI: 10.1016/j.yebeh.2008.07.004

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  15 in total

Review 1.  Update on anticonvulsant drugs.

Authors:  Derek J Chong; Carl W Bazil
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 2.  Postintensive Care Syndrome in Pediatric Critical Care Survivors: Therapeutic Options to Improve Outcomes After Acquired Brain Injury.

Authors:  Cydni N Williams; Mary E Hartman; Kristin P Guilliams; Rejean M Guerriero; Juan A Piantino; Christopher C Bosworth; Skyler S Leonard; Kathryn Bradbury; Amanda Wagner; Trevor A Hall
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.598

3.  Initial Treatment for Nonsyndromic Early-Life Epilepsy: An Unexpected Consensus.

Authors:  Renée A Shellhaas; Anne T Berg; Zachary M Grinspan; Courtney J Wusthoff; John J Millichap; Tobias Loddenkemper; Jason Coryell; Russell P Saneto; Catherine J Chu; Sucheta M Joshi; Joseph E Sullivan; Kelly G Knupp; Eric H Kossoff; Cynthia Keator; Elaine C Wirrell; John R Mytinger; Ignacio Valencia; Shavonne Massey; William D Gaillard
Journal:  Pediatr Neurol       Date:  2017-06-27       Impact factor: 3.372

Review 4.  Levetiracetam in childhood epilepsy.

Authors:  Alberto Verrotti; Ebe D'Adamo; Pasquale Parisi; Francesco Chiarelli; Paolo Curatolo
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

5.  Evaluation of Safety in Exceeding Maximum Adult Doses of Commonly Used Second-Generation Antiepileptic Drugs in Pediatric Patients.

Authors:  Mindl M Messinger; Sunita N Misra; Gary D Clark; Shannon M DiCarlo
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

6.  Trajectories of Health-Related Quality of Life Among Children With Newly Diagnosed Epilepsy.

Authors:  Kristin A Loiselle; Rachelle R Ramsey; Joseph R Rausch; Avani C Modi
Journal:  J Pediatr Psychol       Date:  2016-03-27

Review 7.  Pharmacotherapy for Focal Seizures in Children and Adolescents.

Authors:  Clare E Stevens; Carl E Stafstrom
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

8.  New treatment options for lennox-gastaut syndrome.

Authors:  Monica E Lemmon; Eric H Kossoff
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

9.  Efficacy and safety of levetiracetam in pediatric epilepsy.

Authors:  Ahmed A Elberry; Rawabi K Felemban; Rawan H Hareeri; Sawsan M Kurdi
Journal:  Saudi Pharm J       Date:  2011-06-15       Impact factor: 4.330

10.  Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age.

Authors:  Justine Cormier; Catherine J Chu
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-21       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.